Blog | Oncotarget

Oncotarget News

New Study Suggests Panitumumab with Low-Dose Capecitabine as a Safer, Effective Maintenance Treatment for Advanced Colorectal Cancer

February 18, 2025

Using Panitumumab with metronomic Capecitabine is considered an accepted maintenance regimen in wild type Ras metastatic colorectal cancer regardless of the primary site.”BUFFALO, NY - February 18, 2025 – A new... read more

Oncotarget

SETDB1 Amplification Identified as a Potential Target for New Osteosarcoma Treatment

February 14, 2025

Our team has demonstrated the presence of SETDB1 abnormalities, particularly its amplification, through WES analysis of osteosarcoma human samples and cell lines.”BUFFALO, NY - February 14, 2025 – A new review... read more

Oncotarget

Rare Case of Donor Cell-Derived Blood Cancer Discovered Nine Years After Stem Cell Transplant

February 10, 2025

An uncommon side effect of allogeneic hematopoietic cell transplantation is donor cell-derived hematologic neoplasm (DCHN), which develops when donor hematopoietic cells undergo oncogenic transformation.”BUFFALO, NY - February 10, 2025 – A... read more

Oncotarget

New Genetic Mutation Linked to Drug Resistance in Non-Small Cell Lung Cancer Patient

February 6, 2025

Here we present a case of a patient with stage IV CD-74-ROS1 fusion NSCLC discovered initially with RNA next generation sequencing (NGS) who acquired resistance to lorlatinib after 6 months... read more

Oncotarget

Tracking cfDNA Release Dynamics During Colorectal Cancer Surgery

January 27, 2025

Taken together, our results suggest that in addition to physiological age, comorbidities and unfavorable clinical traits, intense surgical manipulation from the tumor's extent, may result in greater tissue damage and... read more

Oncotarget

HER2-Low Breast Cancer: Genomic Insights and Evolving Treatment Paradigms

January 22, 2025

Human epidermal growth factor receptor 2 (HER2)-low breast cancer has recently emerged as a new clinical subtype of breast cancer, benefiting from treatment with novel anti-HER2 antibody-drug conjugates.”BUFFALO,... read more

Oncotarget

Anti-Correlation Between KLRG1 and PD-1 in Tumor CD8 T Cells

January 21, 2025

The anti-correlation of PD-1 and KLRG1 expression in human tumor infiltrating CD8 T cells suggests the potential for combination therapy supra-additive benefits of anti-PD-1 and anti-KLRG1 therapies.”BUFFALO, NY - January... read more

Oncotarget

Pitfalls of FDA-Approved Germline Cancer Predisposition Tests

December 30, 2024

The FDA approval on September 29, 2023, for 'class III de novo' blood tests to assess hereditary cancer risk make widely available tests that may be obtained through a Direct... read more

Oncotarget

Breakthroughs in Cell-Penetrating Monoclonal Antibody Therapies

December 11, 2024

Monoclonal antibodies (mAb) have emerged as a promising tool in advancing personalized medicine.”BUFFALO, NY - December 11, 2024 – A news feature on the research paper “Next-generation cell-penetrating antibodies for tumor... read more